当前位置: X-MOL 学术BioMed Res. Int. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study.
BioMed Research International ( IF 3.246 ) Pub Date : 2020-07-02 , DOI: 10.1155/2020/7804932
Takashi Kawahara 1 , Shuko Yoneyama 1 , Yoshio Ohno 2 , Junpei Iizuka 3 , Yasunobu Hashimoto 4 , Hideyasu Tsumura 5 , Ken-Ichi Tabata 5 , Yoshihiro Nakagami 2 , Kazunari Tanabe 3 , Masatsugu Iwamura 5 , Hiroji Uemura 1 , Yasuhide Miyoshi 1
Affiliation  

Background. The CHAARTED and LATITUDE trials demonstrated a prolonged overall survival (OS) for metastatic hormone-naïve prostate cancer (mHNPC) patients who receive up-front docetaxel or abiraterone acetate. These studies used their own risk criteria: CHAARTED trial defines high- and low-volume diseases and LATITUDE trial targeting a high-risk disease. The present study explored whether or not the CHAARTED and LATITUDE criteria were useful for predicting the outcome in Japanese bone mHNPC patients, including elderly patients (≥70 years). Methods. A total of 532 mHNPC patients diagnosed from 2004 to 2014 in multithird referral cancer centers were enrolled in this study. All patients had bone metastasis and received combined androgen blockade treatment as an initial hormonal therapy. Results. The number of patients with CHAARTED low-volume and high-volume diseases was 178 (33.5%) and 354 (66.5%), respectively. On the contrary, the number of patients with LATITUDE low-risk and high-risk diseases was 157 (29.5%) and 375 (70.5%), respectively. A total of 307 (57.7%) patients were defined as having both CHAARTED high-volume and LATITUDE high-risk disease. The median castration-resistant prostate cancer- (CRPC-) free survival was 12.5 months for the CHAARTED high volume, 56.9 months for the CHAARTED low volume, 13.6 months for the LATITUDE high risk, and 37.3 months for the LATITUDE low risk, respectively. The OS was 50.1 months in patients with CHAARTED high-volume disease, 95.1 months in patients with CHAARTED low-volume disease, 54.0 months in patients with LATITUDE high-risk disease, and 92.7 months in patients with LATITUDE low-risk disease, respectively. This trend was also observed in elderly (≥70 years old) patients. Conclusions. The patients with CHAARTED high-volume disease or LATITUDE high-risk disease showed a shorter CRPC-free survival and a shorter OS than those in the CHAARTED low-volume disease group or in the LATITUDE low-risk group among Asian Japanese bone metastatic HNPC patients.

中文翻译:

LATITUDE 和 CHARTED 风险标准的预后价值,用于预测接受联合雄激素阻断治疗的骨转移性激素初治前列腺癌患者的生存率:来自日本多机构研究的真实世界数据。

背景。CHARTED 和 LATITUDE 试验表明,预先接受多西他赛或醋酸阿比特龙的转移性激素初治前列腺癌 (mHNPC) 患者的总生存期 (OS) 延长。这些研究使用了他们自己的风险标准:CHARTED 试验定义了高风险和低风险疾病,而 LATITUDE 试验则针对高风险疾病。本研究探讨了 CHARTED 和 LATITUDE 标准是否可用于预测日本骨 mHNPC 患者(包括老年患者(≥70 岁))的结果。方法。2004 年至 2014 年,共有 532 名在多第三方转诊癌症中心诊断出的 mHNPC 患者参加了这项研究。所有患者均发生骨转移,并接受联合雄激素阻断治疗作为初始激素治疗。结果. CHARTED 低容量和高容量疾病的患者人数分别为 178 (33.5%) 和 354 (66.5%)。相反,LATITUDE低危和高危疾病的患者人数分别为157人(29.5%)和375人(70.5%)。共有 307 名 (57.7%) 患者被定义为同时患有 CHARTED 高容量和 LATITUDE 高危疾病。中位去势抵抗性前列腺癌 (CRPC-) 无去势生存期分别为 CHARTED 高容量组 12.5 个月、CHARTED 低容量组 56.9 个月、LATITUDE 高风险组 13.6 个月和 LATITUDE 低风险组 37.3 个月。CHARTED 高容量疾病患者的 OS 为 50.1 个月,CHARTED 低容量疾病患者为 95.1 个月,LATITUDE 高风险疾病患者为 54.0 个月,92 个月。LATITUDE 低危疾病患者分别为 7 个月。在老年(≥70 岁)患者中也观察到这种趋势。结论。在亚洲日本骨转移性 HNPC 患者中,与 CHARTED 低体积疾病组或 LATITUDE 低风险组相比,CHARTED 高容量疾病或 LATITUDE 高危疾病患者的无 CRPC 生存期和 OS 更短.
更新日期:2020-07-02
down
wechat
bug